An Observational Study of Patients With Chronic Kidney Disease
Launched by TARGET PHARMASOLUTIONS, INC. · Mar 7, 2023
Trial Information
Current as of July 28, 2025
Not yet recruiting
Keywords
ClinConnect Summary
The TARGET-KIDNEY study is an observational research project that aims to understand the experiences and outcomes of patients living with chronic kidney disease (CKD) and end-stage kidney disease (ESKD). This study will not involve any new treatments; instead, it will collect information from patients to help improve care for others with these conditions. The study is currently not recruiting participants, and it is open to adults aged 65 and older who have been diagnosed with CKD or ESKD.
To be eligible, participants must have a confirmed diagnosis of CKD or ESKD and be able to give written consent to join the study. During the study, participants can expect to share their experiences and complete surveys about their health over a period of time. It’s important to know that if a participant chooses to stop participating or does not complete the required surveys, they may be withdrawn from the study. Overall, this study hopes to gather valuable insights that can help improve the quality of life for patients with kidney disease.
Gender
ALL
Eligibility criteria
- • Disease Cohort
- Inclusion Criteria:
- • Adult\* patients at the time of enrollment with a diagnosis of CKD/ESKD by ICD-10 code in the EHR interface
- Exclusion Criteria:
- • Death
- • Manual removal (sponsor or site request)
- • No EHR interface encounter \> 3 years
- • Engaged Cohort
- Inclusion Criteria:
- • Adult \* patients diagnosed and managed for CKD/ESKD invited to participate
- • Ability to provide written informed consent
- Exclusion Criteria:
- • Patient expressed desire to withdraw consent to complete PROs
- • Failure to complete PROs within 24 weeks of initial invitation
- • Greater than 24 months lapse of survey completion after baseline surveys completed
- • Additionally, the criteria detailed for Disease Cohort apply to the Engaged Cohort
About Target Pharmasolutions, Inc.
Target Pharmasolutions, Inc. is a leading clinical trial sponsor dedicated to advancing pharmaceutical research and development. With a focus on innovative solutions, the company specializes in providing comprehensive clinical trial management services that enhance the efficiency and effectiveness of drug development. Target Pharmasolutions leverages cutting-edge technology and a team of experienced professionals to ensure regulatory compliance and optimize patient engagement, ultimately facilitating the successful delivery of new therapies to market. Committed to quality and integrity, the company partners with biopharmaceutical organizations to support their clinical goals and drive transformative outcomes in healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials